REGENERON PHARMACEUTICALS, INC. (REGN) Factsheet
Earnings-call transcript: none · IR deck: cataloged — watch a real agent read these end-to-end →
REGENERON PHARMACEUTICALS, INC. (REGN) Stock Analysis
Analysis from 10-Q filed 2026-07-30. Data as of Q2 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 9.7%. FCF margin 24.2%. D/E 0.1x. Source: 10-Q filed 2026-07-30.
| Metric | Value | Context |
|---|---|---|
| ROIC | 9.7% | Near cost of capital |
| FCF Margin | 24.2% | Strong cash generation |
| Debt/Equity | 0.1x | Conservative leverage |
ROIC 9.7% — Top 25% of sector peers. FCF margin 24.2% — Top 10%.
Explore REGENERON PHARMACEUTICALS, INC.: Earnings History | Filings
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for REGN: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: REGENERON PHARMACEUTICALS, INC. earns 9.7% ROIC, Top 25% in Healthcare
ROIC TTM 9.7%, sector median -7.4%, Top 25%. DuPont: NOPAT margin 20.7% × asset turnover 0.4x. Gross margin 84.9%. Operating margin 24.7%. Source: 10-Q filed 2026-07-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 9.7% | Adequate | Above sector median of -7.4% |
| Return on Equity (ROE) | 13.9% | Adequate | Moderate equity returns |
| Gross Margin | 84.9% | Excellent | Strong pricing power |
| Operating Margin | 24.7% | Excellent | Efficient operations |
Cash Flow: REGENERON PHARMACEUTICALS, INC. generates $3.8B FCF at 24.2% margin, positive NaN/8 quarters
FCF TTM $3.8B. FCF margin 24.2%, Top 10%. OCF/Net income 1.1x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-07-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 24.2% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $3.8B | Good | Positive cash generation |
| OCF/Net Income | 1.1x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: REGENERON PHARMACEUTICALS, INC. at 0.1x leverage, 69.4x interest coverage
Debt/Equity 0.1x. Net cash $6.0B. Interest coverage 69.4x. Source: 10-Q filed 2026-07-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.1x | Excellent | Conservative capital structure |
| Net Cash Position | $6.0B | Excellent | Net cash positive |
| Interest Coverage | 69.4x | Excellent | Comfortable debt service |
Valuation: REGENERON PHARMACEUTICALS, INC. trades at 18.1x earnings
P/E 18.1x. EV/Sales 4.6x. FCF yield 4.8%. Dividend yield 0.5%. Source: 10-Q filed 2026-07-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| P/E Ratio | 18.1x | Adequate | Reasonable valuation |
| EV/Sales | 4.6x | Good | Growth premium priced in |
| FCF Yield | 4.8% | Good | Lower cash yield |
| Dividend Yield | 0.5% | Adequate | Growth focus over income |
Capital Allocation: REGENERON PHARMACEUTICALS, INC. returns 4.7% shareholder yield, reducing shares 2.9% YoY
Total shareholder yield 4.7% (div 0.5% + buyback 4.2%). Share count -2.9% YoY. Capital returned $3.7B TTM. Source: 10-Q filed 2026-07-30.
| Metric | REGN | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 4.7% | Good | Dividend + buyback yield combined |
| Buyback Yield | 4.2% | Good | Active share repurchases |
| Share Count Change (YoY) | -2.9% | Good | Net share reduction (accretive) |
| Total Capital Returned (TTM) | $3.7B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 9.7% | Top 25% | - |
| Free Cash Flow Margin | 24.2% | Top 10% | 37.0x above |
| Gross Margin | 84.9% | Top 25% | 1.3x above |
| Operating Margin | 24.7% | Top 25% | - |
| Return on Equity (ROE) | 13.9% | Top 50% | - |
| P/E Ratio | 18.1x | N/A | - |
Financial Scorecard
| Metric | REGN | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 9.7% | Adequate | Top 25% of sector (median: -7.4%) |
| Free Cash Flow Margin | 24.2% | Excellent | Top 10% of sector (median: 0.7%) |
| Gross Margin | 84.9% | Excellent | Top 25% of sector (median: 63.7%) |
| Debt to Equity Ratio | 6.3% | Excellent | Conservative capital structure |
| P/E Ratio (Price-to-Earnings) | 18.1x | Adequate | Fair value |
| Free Cash Flow Yield | 4.8% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is REGENERON PHARMACEUTICALS, INC.'s Return on Invested Capital (ROIC)?
REGENERON PHARMACEUTICALS, INC. (REGN) has a trailing twelve-month Return on Invested Capital (ROIC) of 9.7%. The 8-quarter median ROIC is 11.3% with a declining trend. Sector median -7.4%. Source: 10-Q filed 2026-07-30.
Q: What is REGENERON PHARMACEUTICALS, INC.'s Free Cash Flow Margin?
REGENERON PHARMACEUTICALS, INC. (REGN) has a free cash flow margin of 24.2%, generating $3.8 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-07-30.
Q: What is REGENERON PHARMACEUTICALS, INC.'s P/E ratio and how does it compare to peers?
REGENERON PHARMACEUTICALS, INC. (REGN) trades at a P/E ratio of 18.1x, which is above the sector median of N/A. EV/Sales 4.6x. FCF yield 4.8%. Source: 10-Q filed 2026-07-30.
Q: Does REGENERON PHARMACEUTICALS, INC. pay a dividend?
REGENERON PHARMACEUTICALS, INC. (REGN) currently pays a dividend yield of 0.5%. Total shareholder yield (dividend + buybacks) 4.7%. Source: 10-Q filed 2026-07-30.
Q: What is REGENERON PHARMACEUTICALS, INC.'s revenue and earnings growth?
REGENERON PHARMACEUTICALS, INC. (REGN) grew revenue by 9.3% year-over-year. EPS +1.9% YoY. Source: 10-Q filed 2026-07-30.
Q: Is REGENERON PHARMACEUTICALS, INC. buying back stock?
REGENERON PHARMACEUTICALS, INC. (REGN) repurchased $3.3 billion of stock over the trailing twelve months. This represents a buyback yield of 4.2%. Share count -2.9% YoY. Source: 10-Q filed 2026-07-30.
Q: How does REGENERON PHARMACEUTICALS, INC. compare to competitors in Healthcare?
Compared to other companies in Healthcare, REGENERON PHARMACEUTICALS, INC. (REGN) shows: ROIC 9.7%, sector median -7.4% (Top 25%). FCF margin 24.2%, sector median 0.7% (Top 10%). Gross margin 84.9%, 21.1pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with REGENERON PHARMACEUTICALS, INC.?
Quantitative warning flags for REGENERON PHARMACEUTICALS, INC. (REGN): 1) ROIC declining -2.3% over 8 quarters. Source: 10-Q filed 2026-07-30.
Data Source: Data sourced from 10-Q filed 2026-07-30. TTM metrics as of Q2 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.